Biological effects of novel "combi-targeting" molecule and its effect on DNA repair pathway in hormone-refractory
Youqiang Fang1, Jieying Wu1, Tengcheng Li1
1Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630, Guangdong, China.
Objective:
This study aimed to investigate the biological effects of "combi-targeting" JDF12 and its effect on the DNA repair pathway in hormone-refractory prostate cancer (HRPC).
Methods:
HRPC cell lines (PC3 cells and VCap cells) were treated with JDF12 at different concentrations, and SRB method was employed to detect the proliferation of HRPC cells; Annexin V-FITC kit was used to detect the apoptosis of PC3 cells; Alkaline comet assay was performed to detect DNA damage; Western blot assay was done to detect the expressions of autophosphorylated EGFR, XRCC1 and ERCC1 (later two are proteins in DNA repair pathway); the anti-tumor effect was evaluated in nude mice inoculated with PC3 cells.
Results:
JDF12 could inhibit the proliferation of PC3 cells and VCap cells in a concentration dependent manner (IC50: 14.04 ± 1.22 for PC3 and 15.57 ± 1.13 for VCap) and significantly increase the apoptotic cells as compared to those treated with mitozolomide or iressa alone. In PC3 cells, JDF12 induced DNA damage and also inhibited the expressions of phosphorylated EGFR, XRCC1 and ERCC1 in a concentration dependent manner. Moreover, JDF12 markedly inhibited tumor growth in nude mice.
Conclusion:
The novel "combi-targeting" JDF12 may exert more potent anti-proliferative effect as compared to mitozolomide or iressa alone, and the inhibitory effect on the EGFR signaling pathway and down-regulated XRCC1 and ERCC1 expressions may be ascribed to the JDF12 induced DNA damage.
Insights
The novel "combi-targeting" agent JDF12 shows potent anti-proliferative effects in hormone-refractory prostate cancer (HRPC) by inducing DNA damage and inhibiting key repair proteins. This agent demonstrates significant tumor growth inhibition in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Hormone-refractory prostate cancer (HRPC) remains a significant clinical challenge with limited treatment options.
- Targeting DNA repair pathways is a promising strategy for overcoming therapeutic resistance in cancer.
Purpose of the Study:
- To investigate the biological effects of the novel "combi-targeting" agent JDF12.
- To evaluate the impact of JDF12 on the DNA repair pathway in HRPC.
- To assess the anti-tumor efficacy of JDF12 in preclinical models.
Main Methods:
- HRPC cell lines (PC3 and VCap) were treated with JDF12.
- Cell proliferation was assessed using the SRB assay.
- Apoptosis was detected using Annexin V-FITC staining.
- DNA damage was evaluated via alkaline comet assay.
- Western blot analysis measured the expression of phosphorylated EGFR, XRCC1, and ERCC1.
- In vivo anti-tumor activity was tested in a xenograft mouse model.
Main Results:
- JDF12 inhibited proliferation and induced apoptosis in HRPC cell lines in a dose-dependent manner.
- JDF12 treatment led to significant DNA damage.
- The agent downregulated phosphorylated EGFR, XRCC1, and ERCC1 expression.
- JDF12 markedly inhibited tumor growth in vivo.
Conclusions:
- JDF12 exhibits potent anti-proliferative and anti-tumor effects in HRPC.
- The mechanism involves inducing DNA damage and downregulating DNA repair proteins (XRCC1 and ERCC1) and EGFR signaling.
- JDF12 may offer a more effective therapeutic strategy compared to existing agents.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:56Treatment Resistant Cancers
02:38Mitogens and the Cell Cycle
01:22Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...